Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversibly binding P2Y12 platelet inhibitor. It is used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Primary Indications
* **Acute Coronary Syndrome (ACS):** In combination with aspirin, for the reduction of thrombotic cardiovascular events in patients with ACS.
* **Secondary Prevention of MI:** In patients with a history of MI (greater than 1 year ago) who are at high risk for occlusive vascular events, in combination with aspirin.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months. After 12 months, consider continuing 90 mg twice daily or 60 mg twice daily based on individual patient risk for ischemic events and bleeding.
* **Post-MI (historically treated for ACS) or History of MI (at least 1 year ago):**
* **Maintenance Dose:** 60 mg orally twice daily. Therapy duration should be individualized based on patient risk factors.
## Pediatric Dosing
* There is no established use or dosing for ticagrelor in pediatric patients.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is needed in mild to severe renal impairment.
* **Hepatic Impairment:** No dose adjustment is needed in mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
## Contraindications
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Known hypersensitivity to ticagrelor or any component of the formulation.
## Adverse Effects
* **Most Common:** Bleeding (including fatal and life-threatening), dyspnea, bradycardia.
* **Serious:** Major bleeding, ventricular pauses, increased serum creatinine.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Potent inhibitors (e.g., ketoconazole, ritonavir) can increase ticagrelor exposure; potent inducers (e.g., rifampin, carbamazepine) can decrease exposure.
* **CYP3A4 Substrates:** Ticagrelor inhibits CYP3A4, increasing exposure to substrates (e.g., simvastatin, atorvastatin).
* **Aspirin:** Concurrent use is indicated for ACS and secondary prevention. Dose above 100 mg daily in patients treated with ticagrelor may increase bleeding risk.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding.
* **Statins:** Monitor for potential increased statin exposure and myopathy.
## Monitoring
* **Bleeding:** Assess for signs and symptoms of bleeding, especially in patients with increased bleeding risk factors.
* **Bradycardia:** Monitor heart rate.
* **Renal and Hepatic Function:** Baseline and periodically as clinically indicated.
## Clinical Pearls
* Ticagrelor is a P2Y12 inhibitor, not a thienopyridine, and does not require hepatic activation.
* Dose of aspirin should generally not exceed 100 mg daily in patients receiving ticagrelor, except in specific circumstances (e.g., acute coronary syndrome loading).
* Discontinuation of ticagrelor prematurely increases the risk of stent thrombosis, MI, and death.
* The 60 mg twice daily dose is generally reserved for patients who have completed 12 months of dual antiplatelet therapy or those with a history of MI at least 1 year prior.
* Assess bleeding risk carefully; consider dose reduction to 60 mg BID for patients at high bleeding risk who have completed 12 months of treatment.
**Disclaimer:** This information is intended for healthcare professionals. Always consult the official prescribing information and institutional protocols for the most current and comprehensive guidance.
